BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 24432872)

  • 21. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
    Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
    N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
    Cohen AT; Dobromirski M
    Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
    Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
    N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Managing pulmonary embolism from presentation to extended treatment.
    Cohen AT; Dobromirski M; Gurwith MM
    Thromb Res; 2014 Feb; 133(2):139-48. PubMed ID: 24182642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
    Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
    Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rivaroxaban for the treatment of pulmonary embolism.
    Vanassche T; Verhamme P
    Adv Ther; 2013 Jun; 30(6):589-606. PubMed ID: 23807375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute pulmonary embolism treatment with rivaroxaban results in a shorter duration of hospitalisation compared to standard therapy: an academic centre experience.
    Paczyńska M; Kurnicka K; Lichodziejewska B; Goliszek S; Dzikowska-Diduch O; Sobieraj P; Burzyński Ł; Kostrubiec M; Pruszczyk P; Ciurzyński M
    Kardiol Pol; 2016; 74(7):650-6. PubMed ID: 26779849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis.
    Mismetti P; Quenet S; Levine M; Merli G; Decousus H; Derobert E; Laporte S
    Chest; 2005 Oct; 128(4):2203-10. PubMed ID: 16236875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.
    Ramacciotti E; Araújo GR; Lastoria S; Maffei FH; Karaoglan de Moura L; Michaelis W; Sandri JL; Dietrich-Neto F;
    Thromb Res; 2004; 114(3):149-53. PubMed ID: 15342210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
    Di Nisio M; Vedovati MC; Riera-Mestre A; Prins MH; Mueller K; Cohen AT; Wells PS; Beyer-Westendorf J; Prandoni P; Bounameaux H; Kubitza D; Schneider J; Pisters R; Fedacko J; Fontes-Carvalho R; Lensing AW
    Thromb Haemost; 2016 Sep; 116(4):739-46. PubMed ID: 27535349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies.
    Kohn CG; Fermann GJ; Peacock WF; Wells PS; Baugh CW; Ashton V; Crivera C; Schein JR; Wildgoose P; Coleman CI
    Curr Med Res Opin; 2017 Sep; 33(9):1697-1703. PubMed ID: 28665208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions.
    Margolis JM; Deitelzweig S; Kline J; Tran O; Smith DM; Bookhart B; Crivera C; Schein J
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
    Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Muehlhofer E; Kälebo P
    Thromb Res; 2007; 120(5):685-93. PubMed ID: 17292948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.
    Van Thiel D; Kalodiki E; Wahi R; Litinas E; Haque W; Rao G
    Clin Appl Thromb Hemost; 2009; 15(4):389-94. PubMed ID: 19608550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral rivaroxaban for symptomatic venous thromboembolism.
    Landman GW; Gans RO
    N Engl J Med; 2011 Mar; 364(12):1178; author reply 1178. PubMed ID: 21428778
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
    Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
    Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban.
    Merli GJ; Hollander JE; Lefebvre P; Laliberté F; Raut MK; Olson WH; Pollack CV
    Hosp Pract (1995); 2015; 43(2):85-93. PubMed ID: 25791984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Practical management of rivaroxaban for the treatment of venous thromboembolism.
    Imberti D; Benedetti R
    Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis.
    Mantovani LG; Haas S; Kreutz R; Folkerts K; Gebel M; Monje D; Schneider J; van Eickels M; Sahin K; Zell E; Ageno W; Turpie AGG
    Eur J Intern Med; 2019 Mar; 61():29-33. PubMed ID: 30342973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.